Wedzony K, Fijal K, Mackowiak M, Chocyk A, Zajaczkowski W
Institute of Pharmacology Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Smetna 12 Street, Kraków, Poland.
Neuroscience. 2008 Jun 2;153(4):1370-9. doi: 10.1016/j.neuroscience.2008.03.016. Epub 2008 Mar 20.
The malfunction of glutamatergic neurotransmission in the neonatal or postnatal periods may be a risk factor for the appearance of neuroanatomical, neurochemical or functional changes that are characteristic of schizophrenia. Thus, the present study was undertaken to investigate whether blockade of N-methyl-d-aspartate (NMDA) receptors in the postnatal period influences rat behavior in tests characterizing schizophrenia-like deficits such as psychomotor agitation, impairments of sensorimotor gating, working memory, and intensity of social interactions. (E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 40116), a competitive antagonist of NMDA receptors, was given postnatally (1.25 mg/kg on days 1, 3, 6, 9; 2.5 mg/kg on days 12, 15, 18; and finally 5 mg/kg on day 21, all injections s.c.), and rats were tested at 60 days old. We found that blockade of NMDA receptors in the postnatal period led to an enhancement of exploration, mimicking psychomotor agitation, impairments in sensorimotor gating as measured by a prepulse-evoked inhibition of acoustic startle response, and an impaired working memory, as measured by an increase in the latency to achieve accurate rate of response in the delayed alternation task. Decreases in non-aggressive social interactions and increases in aggressive interactions were also observed. In addition to cognitive deficits typical of schizophrenia, rats treated postnatally with NMDA receptor antagonists also showed higher level of fear exhibited in the elevated plus maze. Thus, the blockade of NMDA receptors in the postnatal period may model deficits that are characteristic of schizophrenia.
新生儿期或出生后谷氨酸能神经传递功能障碍可能是精神分裂症特有的神经解剖学、神经化学或功能变化出现的危险因素。因此,本研究旨在探讨出生后N-甲基-D-天冬氨酸(NMDA)受体阻断是否会影响大鼠在表征精神分裂症样缺陷的测试中的行为,如精神运动性激越、感觉运动门控障碍、工作记忆以及社交互动强度。NMDA受体竞争性拮抗剂(E)-2-氨基-4-甲基-5-膦酰基-3-戊烯酸(CGP 40116)在出生后给予(第1、3、6、9天为1.25mg/kg;第12、15、18天为2.5mg/kg;最后在第21天为5mg/kg,均皮下注射),并在60日龄时对大鼠进行测试。我们发现,出生后阻断NMDA受体导致探索行为增强,类似于精神运动性激越,感觉运动门控受损,这通过对惊吓反应的前脉冲诱发抑制来测量,工作记忆受损,这通过延迟交替任务中达到准确反应率的潜伏期增加来测量。还观察到非攻击性社交互动减少和攻击性互动增加。除了精神分裂症典型的认知缺陷外,出生后用NMDA受体拮抗剂治疗的大鼠在高架十字迷宫中也表现出更高水平的恐惧。因此,出生后阻断NMDA受体可能模拟精神分裂症特有的缺陷。